AI chatbot aims to demystify prostate cancer for patients

NCT ID NCT07040501

Not yet recruiting Knowledge-focused Sponsor: Case Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether ChatGPT, an artificial intelligence chatbot, can help men better understand their prostate cancer diagnosis. Fifty men who recently had a prostate biopsy will use the chatbot to review their pathology results. Researchers will measure how accurately patients understand their risk level and whether the chatbot reduces anxiety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ChatGPT (AI chatbot)
What this could lead to: If successful, this could show that AI chatbots are a useful tool to help patients understand their medical results.
What could go wrong: This is a small, early feasibility study with only 50 participants. It does not test a treatment, so it cannot directly improve health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Case Comprehensive Cancer Center, Cleveland Clinic Glickman Urologic Institute

Cleveland, Ohio, 44195, United States

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.